Drugs / Riliprubart
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04802057 | Mar 2021 → Mar 2025 | autoimmune hemolytic anemia | Bioverativ, a Sanofi company | Terminated | No outcome recorded |
| Phase 1 | NCT04269551 | Jun 2020 → Jan 2022 | autoimmune hemolytic anemia | Bioverativ, a Sanofi company | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05156710 | Jun 2022 → Oct 2025 overdue | transplant rejection | Sanofi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04658472 | Apr 2021 → Oct 2025 | chronic inflammatory demyelinating polyradiculoneuropathy | Bioverativ, a Sanofi company | Completed | No outcome recorded |
| Phase 2 | NCT04669600 | Feb 2021 → Feb 2022 | autoimmune thrombocytopenia | Bioverativ, a Sanofi company | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06859099 | Apr 2025 → Oct 2029 expected | polyneuropathy, inflammatory demyelinating, chronic | Sanofi | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT06290141 | Aug 2024 → Jul 2027 expected | polyneuropathy, inflammatory demyelinating, chronic | Sanofi | Recruiting | No outcome recorded |
| Phase 3 | NCT06290128 | Jul 2024 → May 2027 expected | chronic inflammatory demyelinating polyradiculoneuropathy, polyneuropathy, inflammatory demyelinating, chronic | Sanofi | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-06-10 | Sanofi | Results Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy sanofi.com ↗
This decision follows an interim analysis by an independent data monitoring committee, which determined that the MOBILIZE study is unlikely to provide sufficient efficacy. |
| 2025-06-30 | Sanofi | Regulatory Press Release: Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy sanofi.com ↗
Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy |
| 2025-06-25 | Sanofi | Regulatory Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation sanofi.com ↗
The US Food and Drug Administration (FDA) has granted orphan drug designation to riliprubart for the investigational treatment of antibody-mediated rejection (AMR) in solid organ transplantation. |
| 2024-06-25 | Sanofi | Results Media Update: Riliprubart one-year results from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy sanofi.com ↗
Sanofi’s complement C1s inhibitor, riliprubart, showed encouraging efficacy and safety for participants with chronic inflammatory demyelinating polyneuropathy (CIDP) in the latest interim analysis from an ongoing phase 2 study. |
All press releases naming this drug 4 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | riliprubart | “Riliprubart (SAR445088, BIVV020), a second-generation classical complement inhibitor, is a humanized monoclonal antibody that selectively inhibits only the activated form of C1s.” PMID 38085846 ↗ Feb 2024 |
| Known as | BIVV020 | “SAR445088 (BIVV020)” NCT04669600 ↗ |
| Known as | SAR445088 | “Riliprubart (SAR445088, BIVV020), a second-generation classical complement inhibitor, is a humanized monoclonal antibody that selectively inhibits only the activated form of C1s.” PMID 38085846 ↗ Feb 2024 |
| Known as | TNT-020 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5315038 ↗ |
| Action | Inhibit | “selectively inhibits only the activated form of C1s” PMID 38085846 ↗ Feb 2024 |
| Modality | Monoclonal antibody | “is a humanized monoclonal antibody” PMID 38085846 ↗ Feb 2024 |
| Route | Intravenous | “Route of administration: intravenous” NCT04269551 ↗ |
| Target | C1S | “activated form of C1s” PMID 38085846 ↗ Feb 2024 |